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STUDY OF EFFECTS OF ACUTE MYOCARDIAL 
INFARCTION ON CHOLESTEROL AND CHOLESTEROL 
RATIOS 
INTRODUCTION 
 Coronary artery disease remains the most common cause of death despite 
significant advancement in its prevention and treatment 4. 
 Myocardial infarction generally occurs with the abrupt decrease in 
coronary blood flow that follows a thrombotic occlusion of a coronary artery 
previously narrowed by atherosclerosis.  The injury is facilitated by factors such 
as cigarette smoking, hypertension, dyslipidemia, diabetes and a number of 
other factors 70. 
 According to Davidson MA et-al, the risk of coronary artery disease in 
Indians is 3-4 times higher than white Americans and 20 times higher than 
Japanese. 
 Aggressive management of the risk factors is one of the crucial elements 
in the treatment of patients with coronary artery disease.  Serum markers that 
are used for cholesterol risk assessment and management are total cholesterol, 
low density lipoprotein (LDL) cholesterol level and high density lipoprotein 
(HDL) cholesterol level. 
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 Patients with acute myocardial infarctions should have plasma lipid levels 
determined within 24 hours of the onset of symptoms of acute infarction6. 
 The studies like Mulligan IP etal (1984), Jacobson TA etal (1996), Scrass 
R Marshall R etal (1987) and many other studies have questioned the validity of 
the plasma lipid levels measures beyond 24 hours from  the onset of myocardial 
infarction5. 
 The studies have demonstrated that acute myocardial infarction results in 
a transient decline in the serum cholesterol levels, which becomes apparent after 
24 hours of onset  of myocardial  infarction and may last for 2 to 3 months11.  
Therefore in situations in which plasma lipid levels  are not determined within 
24 hours of the onset of myocardial infarction symptoms, the cholesterol 
measurements are  usually deferred until the effect of acute infarction is fully 
resolved which may result in an inappropriate delay in the management of hyper 
cholesterolemia based on Brugada R, Wenger, NK (Cardiology 1996 : 87:  
194-199) 
 The ratios of total cholesterol to HDL cholesterol and of LDL cholesterol 
to HDL cholesterol also can be used as predictors of acute coronary events 
(Based on Castelli WP, AmJ Med 1984:27:4-12, Linn S.Fulwood, Carroll M et 
al, Am J 1991:1038 – 1043) 
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 The purpose of  the present study is to determine whether the acute 
myocardial infarction affects the values of the serum cholesterol ratios as it does 
with absolute serum cholesterol Levels.  
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AIM OF THE STUDY 
1. To study the effect of acute myocardial infarction on absolute cholesterol 
and triglyceride levels. 
2. To study the effect of acute myocardial infarction on the ratios of total 
cholesterol to HDL (High Density Lipoprotein) cholesterol and of LDL 
(Low Density Lipoprotein) cholesterol to HDL (High Density 
Lipoprotein) cholesterol.  
3. To determine whether the acute myocardial infarction affects the values 
of the serum cholesterol ratios as it does with absolute cholesterol level. 
4. To stress dyslipidemia as a major risk factor for coronary artery disease. 
5. To evaluate more about primordial prevention of dyslipidemia. 
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REVIEW OF LITERATURE 
  
 The two coronary arteries that supply the myocardium arise from the 
sinuses behind two of the cusps of the aortic valve at the root of the aorta.  The 
right coronary artery has a greater flow in 50% of individuals and the left has a 
greater flow in 20% and the flow is equal in 30%. 
 
 
The left anterior  descending     -      Anterior wall of left ventricle, 
Coronary artery (40to50%)               anterior 2/3 of inter ventricular  
                                                           Septum.                                               
Left circumflex coronary artery-       Lateral wall of left ventricle. 
(15to20%)                                                       
Right coronary artery                 -       Infero posterior wall of left  
(30% to 40%)                                     ventricle, posterior 1/3 of    
                                                            interventricular septum,  
                                                            Right atrium and right  
                                                            Ventricle. 
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MYOCARDIAL INFARCTION DUE TO CORONARY 
ATHEROSCLEROSIS 
 Myocardial infarction generally occurs with the abrupt decrease in 
coronary blood flow that follows a thrombotic occlusion of a coronary artery 
previously narrowed by atherosclerosis. 
CORONARY ATHEROSCLEROSIS 
 The earliest lesions of atherosclerosis can be found in young children and 
infants in the form of fatty streak whereas the advanced lesion, the fibrous 
plaques generally appears during early adulthood and progress with age45.  
 The abdominal aorta is involved earliest.  The aorta is usually most 
heavily involved at or near the orifice of its branches.  (Particularly at the level 
of coronary arteries). 
 In coronary arteries, raised lesions are most prominent in the main stems, 
the highest incidence being a short distance beyond the ostia.   Atherosclerosis 
is usually found in the epicardial portions of the vessels, while the intra mural 
coronary arteries are spared, Coronary atherosclerosis is often diffuse.  The 
degree to which the lumen is narrowed varies, but once the process has 
commenced, all the intima of the extra mural portions of the vessels is usually 
involved.   Typical atheromatous fibrous plaques also develop in saphenous 
vein, after grafting which is used for aortocoronary by pass graft. 
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HYPOTHESIS OF ATHEROSCLEROSIS 
 The response to injury hypothesis 
The endothelial lining cells are exposed to repeated or continuous insults.   
Dysfunctional endothelial cells at the susceptible sites in the arterial tree would 
lead to exposure of the subendothelial tissue to increased concentrations of 
plasma constituents77.  This triggers a sequence of events including monocytes 
and platelet adherence, migrations, platelet aggregation and formation of 
microthombi and release of secretary products.  This causes proliferation of 
smooth muscle cells at these sites of injury.  Monocytes become transformed to 
foam cells.  Thus a well developed plaque is formed. 
 Monoclonal hypothesis 
  This states that the intimal proliferative lesion results from the 
Multiplication of single, individual smooth muscle cells, as do benign tumors78.   
According to this hypothesis,  the intimal smooth muscle cell that proliferate to 
form an atheroma are normally under feed back control by mitosis inhibitors 
formed by the smooth  muscle cells in the continuous media and this feed back 
control system tends to fail with age as these controlling cells die and are not 
adequately replaced. 
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RISK FACTORS 
 A number of conditions and habits are present more frequently in 
individuals who develop atherosclerosis than in general population; these 
factors have been termed risk factors. 
RISK FACTORS FOR ACUTE MYOCARDIAL INFARCTION 62, 71 
CATEGORY I 
Non modifiable risk factors 
- Age 
- Male gender 
- Family history of early onset coronary artery disease 
- Low socioeconomic status 
Modifiable risk factors 
- ↑ Low density lipoprotein 
- ↓ High density lipoprotein 
- Atherogenic diet 
- Cigarette smoking 
- Hypertension 
- Left ventricular hypertrophy 
- Thrombogenic factors 
 9
CATEGORY II 
- Diabetes mellitus 
- Physical iactivity 
- Elevated triglycerides 
- Obesity 
CATEGORY III 
- Psychosocial factors 
- Lipoprotein (a) 
- Homocysteine 
- Inflammatory markers – especially C-reactive protein 
- No alcohol comsumption 
- Oxidative stress 
- Post menopausal status – because of reduction in plasma oestrogen 
levels. 
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DYSLIPIDEMIA 
 Dyslipidemia is defined as an abnormal plasma lipid status.   Common 
lipid abnormalities include elevated levels of total cholesterol, low density 
lipoprotein (LDL) cholesterol, lipoprotein (a) and triglyceride; low levels of 
high density lipoprotein (HDL) cholesterol and a preponderance of small, dense 
particles.  These abnormalities can be found alone or in combination1. 
 Approximately 50% of U.S adults have an elevated total cholesterol level 
and the vast majority of patients with atherosclerotic vascular disease have some 
form of dyslipidemia.   
 Despite marked benefits of lipid therapy, 70% of individuals with 
dyslipidemia fail to meet the LDL cholesterol targets established by the 
National Cholesterol Education Program Adult Treatment Panel III  
(NCEP ATP III) 73 
RISK FACTORS 
 Elevated levels of total cholesterol and LDL cholesterol and low levels of 
HDL cholesterol are major modifiable lipid risk factors for coronary artery 
disease3. 
 It has been estimated that for each 1% decrease in LDL cholesterol and 
for each 1% increase in the HDL cholesterol, the risk for cardiovascular events 
is reduced by 2% and 3% respectively. 
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 So routine lipoprotein analysis is recommended by the NCEP ATP III for 
all adults aged 20 years and older, as dyslipidemia is usually asymptomatic 
condition and early recognition and treatment improves prognosis30. 
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LIPID THERAPY AND THE NEW CORONARY ARTERY 
DISEASE PARADIGM 
 It has been now established that the most dangerous rupture, prone 
atherosclerotic plaques are not necessarily those causing the most severe 
narrowing and that most of acute coronary syndromes are caused by lesions that 
were less than 70% stenotic prior to ulceration and thrombosis.  Non obstructive 
plaques with extensive inflammation (Stimulated by oxidized lipoproteins in the 
vessel wall), lipid rich cores and thin fibrous caps are more prone to ulceration 
and rupture than longstanding obstructive lesions with extensive calcification 
and thick fibrous caps comprised of dense collagenous tissue78. 
 Moderate reductions in low density lipoprotein (LDL) cholestrol slow the 
progression of coronary artery disease in most patients and lesion regression is 
more frequent with LDL cholesterol reduction.  Nevertheless, the beneficial 
effects of lipid therapy are due more to plaque stabilization than to changes in 
stenos is severity, which are generally modest and disproportionate to the 25- 
80% reduction in major cardiovascular events72. 
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 Plaque stabilization, which can be accomplished in weeks to months with 
aggressive treatment of dyslipidemia may be related to resorption of 
macrophage and extra cellular lipid deposits, a decrease in neointimal 
inflammation and maintenance of fibrous cap integrity. 
 Effective treatment transforms the inflamed, friable plaque into a stable 
fibrotic plaue that is less prone to ulceration, rupture and thrombosis.  In 
addition lipid lowering therapy, improves endothelial dysfunction caused by 
dyslipidemia, resulting in additional vasodilatory, anti thrombotic and anti-
inflammatory effects.  For patients with coronary artery disease, treatment of 
dyslipidemia and other concomitant risk factors is essential to improve long 
term prognosis29. 
 Several large, randomized, places to controlled trials of statin therapy 
have shown reductions in cardiovascular morbidity with lipid therapy in both 
primary and secondary prevention2. 
 Despite minor improvements in lesion severity, lipid lowering therapy 
results in marked (25-80%) reductions in major cardiovascular events primarily 
due to plaque stabilization42. 
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FAMILY OF LIPIDS 
AN OVERVIEW 
CHOLESTEROL 
 It is the most abundant sterol in animal kingdom.  It is not present in plant 
oils.  It was first isolated from human gallstones.  The total amount of 
cholesterol in human beings is about 130-160gm.  The concentration in various 
major tissues is as follows.  
 PERCENT WT.GM 
Brain and nervous system 
Muscle  
Blood 
Liver 
Adrenal gland 
Skin 
Heart, lungs, kidneys, Spleen 
 2% 
0.1% 
0.21% 
0.3% 
10% 
0.3% 
0.25% 
32g 
30g 
11.3g 
5.1g 
1.2g 
12g 
5g 
  
  Cholesterol in serum can be quantitatively determined with ‘kit’ method 
which uses enzyme procedure. 
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 Cholesterol as an abundant constituent of brain, nerves and spinal cord it 
functions as an insulating covering of impulse generations and transmitting 
structure. 
 
TRIGLYCERIDES 
 These are formed by esterification of glycerol with fatty acids, which 
have a hydrocarbon group attached to carboxyl group.  It is the major lipid in 
chylomicrons and VLDL and serves as energy substrate in liver and peripheral 
tissues particularly muscle.  Excess energy is stores as triglyceride in adipose 
tissue (about 6kg). 
 
PHOSPHOLIPIDS 
 They are essential components of cell membrane.  Vast majority of 
lipoprotein surface is formed of phospholipids that form monolayers, acting as 
interface with both plasma components and non-polar lipids of lipoprotein care. 
 
APOPROTEINS 
 Apoproteins play important roles in lipoprotein structure, stabilization, 
metabolism including enzyme activation or inhibition or act as ligand for 
lipoprotein receptors. 
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MAJOR APOPROTEINS AND THEIR FUNCTIONS 
 
Number of 
amino 
acids 
Approx. 
Molecular 
Weight(Da) 
Origin 
Lipoprotein 
distribution 
Principal 
function 
A-I 
 
243 28,000 Liver, Intestine HDL, Chylomicrons LCAT activator 
A-II 154 17,000 Liver, Intestine HDL, Chylomicrons Structural protein in 
HDL 
A-IV 391 40,000 Liver, Intestine HDL, Chylomicrons Non-specific LCAT 
cofactor 
B48 2152 2,46,000 Intestine Chylomicrons, 
Chylomicron  
Remnants 
Mediates chylomicron 
formation and secretion 
B100 4536 5,13,000 Liver VLDL, LDL Mediates hepatic VLDL 
formation legand for 
LDL receptor 
C-I 57 7000 Liver Chylomicrons 
VLDL, HDL 
Inhibitor of 
chylomicron uptake 
C-II 78 9000 Liver Chylomicrons 
VLDL, HDL 
LPL activator 
C-III 79 9000 Liver Chylomicrons 
VLDL, HDL 
? Inhibitor of LPL 
D ? 2000 Liver HDL ? Involved in 
cholesterol ester 
transfer 
E 299 3400 Liver Chylomicrons 
VLDL, HDL 
Ligand for chylomicron 
receptor and LDL 
receptor 
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STRUCTURE OF   LIPOPROTEIN PARTICLE 
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CHARACTERISTICS OF LIPOPROTEINS 
   
Chemical composition (% of dry mass) 
Class 
Diameter 
(A0) 
Density 
(g/ml) 
Electro-
Phoretic
mobility
Trigly- 
cerides 
Choles- 
terol 
Choles-
terol 
Phospho 
lipids 
Proteins
Chylo 
microns 
800-5000 0.930 α 2 86 3 2 7 2 
VLDL 300-800 0.960- 
1.006 
preβ 55 12 7 18 8 
IDL 250-350 1.006- 
1.019 
Slow 
preβ 
23 29 9 19 19 
LDL 216 1.019- 
1.063 
β 6 42 8 22 22 
HDL2 100 1.063- 
1.125 
α ι 5 17 5 33 40 
HDL3 75 1.125- 
1.210 
α1 3 13 4 25 55 
Lp (a) 300 1.055- 
1.085 
Slow 
preβ 
3 33 9 22 33 
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PLASMA LIPID ENZYMES 
1. LIPOPROTEIN LIPASE 
It converts lipoprotein tryglycerides in to free fatty acids and monoacids 
by peripheral tissues.  It is synthesized in adipose tissue and in the muscle.  It is 
transported by ill defined mechanism to surface of capillary endothelial cells 
where it interacts with triglyceride rich lipoproteins. 
2. HEPATIC TRIGLYCERIDE LIPASE 
 It functions as triglyceride hydrolase and phospholipase.  It is an enzyme 
with homology to lipoprotein lipase that is synthesized in the liver. Its 
physiological actions are to remove triglycerides and phospholipids from 
chylomicrons and VLDL remnants and to possibly augment chylomicron uptake 
by liver. 
3. CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) 
 It is synthesized in liver and is an important plasma protein that mediates 
the exchange of triglycerides in VLDL, chylomicrons and remnants for 
cholesterol esters in HDL and LDL. 
4. LECITHIN CHOLESTEROL ACYL TRANSFERASE (LCAT) 
 It converts HDL cholesterol into cholesterol ester.  The newly formed 
cholesteryl ester can move from surface of high density lipoprotein to the core, 
allowing the particles to adsorb more free cholesterol on to their surface. 
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Schematic representation of Exogenous Lipid 
Transport & Metabolism 
LP Lipase : Lipoprotein Lipase 
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Lipid Transport – Endogenous Pathway (Diagrammatic Pathway) 
LPL – Lipoprotein Lipase,  HL – Hepatic Lipase 
CETP – Cholesterol Ester Transport Protein 
FFA – Free Fatty Acids 
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ROLE OF RECEPTORS IN LIPID DISORDERS 
 
THE LDL RECEPTOR 
 Of all lipoprotein receptors, the most important is the low density 
lipoprotein (LDL) receptor.  It is a highly regulated receptor and takes major 
part in cholesterol metabolism. 
 It is present in almost on all cell membrane though in variable number.  
The amino terminal of clathrin present on the cytosolic side of the receptor is 
exposed outside which works as the binding site for APO-B-100, but not for 
other apportions including APO-B-48.  After binding with the receptor, the LDL 
molecule is taken in as a whole by the process of endocytosis.   After leaving 
the LDL particle in the cytosol, the receptor returns back to the original site, so 
in this process the receptor is not destroyed but recycled. 
 When the intracellular cholesterol level rises, LDL receptor activity is 
down regulated and when the intra cellular cholesterol falls, LDL receptor 
activity is upgraded. 
 High Density  Lipoprotein (HDL)  transfers cholesterol to the VLDL and 
chylomicron but ultimately to the LDL  which is taken in via the LDL receptor. 
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ABNORMAL LDL AND ROLE OF RECEPTORS 
 Normal LDL does not cause foam cell formation when incubated with 
cultured macrophages or smooth muscle, but when the LDL undergoes lipid 
peroxidation (Oxidized LDL) it becomes a ligand for an alternative scavenger 
pathway for uptake into the cells. 
 These scavenger receptors are present on the endothelial cells and 
macrophages.  This pathway is less regulated than the LDL receptor pathway. 
 Though LDL is the most harmful lipoprotein, elevated VLDL and 
Triglycerides possibly enhances atherosclerosis.  It has been seen that 
cholesteryl esters enriched VLDL isolated form cholesterol fed animals can be 
taken by receptors on macrophages and smooth muscle cells and cause foam 
cell formation. 
 This cholesteryl ester rich VLDL is enriched in APO-E and is probably 
the representative of VLDL remnant.  This APO-E receptor has been termed as 
a LDL receptor related protein (LRP).  APO-E rich lipoproteins bind to LRP 
and thereby help in the uptake of his remnants by the liver. 
 Familial hyper cholesterolemia and familial defective APO-E-100 are the 
disorders related to receptor abnormality. 
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LIPID DISORDERS AND DYSLIPIDAEMIAS 
 
 Hyperlipidaemia or hyperlipoproteinaemias are disturbances of lipid 
transport that result from the accelerated synthesis or retarded degradation of 
lipoproteins that transport cholesterol and triglycerides through plasma.   
Hyperlipidaemia consists of an excessive accumulation of one or more of the 
major lipids transported in plasma and is a manifestation of one or more 
abnormalities of metabolism or transport. 
 It is not easy to define the exact cut off point for high cholesterol or 
triglycerides.    However as a working rule hyperlipoproteinaemia is considered 
to be present whenever the plasma cholesterol level exceeds 5.2 mmol/L.  
(200mg/dl) or the triglyceride level exceeds 2.2 mmol/l (200mg/dl). 
 The value of cholesterol represents the total cholesterol, which includes 
both cholesterol esters and unesterified cholesterol. 
 An isolated elevation in plasma trigylcerides indicates that the 
concentration of chylomicrons or VLDL is increased.  On the other hand, an 
isolated elevation of plasma cholesterol nearly always indicates that the 
concentration of LDL is increased. 
 The various combinations of elevated lipoproteins have been divided into 
six lipoprotein types or patterns by Freidrickson on the basis of specific 
electrophoretic patterns of the various plasma lipoproteins. 
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PATTERNS OF LIPOPROTEINS IN PLASMA 
IN HYPERLIPOPROTEINEMIAS 
  
MAJOR ELEVATIONS IN PLASMA LIPOPROTEIN 
PATTERN Lipoprotein Lipid 
Type – I Chylomicrons Triglycerides 
 
Type – II a LDL Cholesterol 
 
Type – II b LDL and VLDL Cholesterol and Triglyceride 
TG/Chol<5:1 
Type – III  Chylomicrons 
remnants & IDL 
TG and Cholesterol 
TG/Chol > 5:1 
Type – IV  VLDL Triglycerides (TG) 
 
Type – V  VLDL and 
Chylomicrons 
Triglycerides (TG) and 
Cholesterol  TG/Chol > 5:1 
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PATHOPHYSIOLOGICAL CLASSIFICATION OF THE 
HYPERLIPIDAEMIA 
Disorders 
Mechanism 
Primary Secondary 
Lipoprotein 
Abnormalities 
Common 
Xanthomas 
Early 
Athero 
sclerosis 
Increased  
triglyceride 
production  
 Increased  
Endogenous 
VLDL 
synthesis 
Familial 
Hypertri- 
glyceridemia 
Hyper insulinemic 
states Obestiy 
Estrogen therapy  
Glucocorticoid  
therapy  Type 2 DM, 
treated Growth 
Hormone excess  
Alcoholism 
Pregnancy 
Increased  
VLDL 
Increased VLDL
And 
chylomicrons 
None; 
eruptive 
None ? 
Decreased  
triglyceride 
removal  
Abnormal 
LPL function 
LPL 
deficiency  
LPLactivator 
(apo C II) 
deficiency  
LPL 
Inhibitation 
Low insulin (untreated 
diabetes mellitus)  
Hypothyroidism 
Uremia 
Dysglobulinaemia 
(systemic 
erythematosus, 
myeloma, lymphoma, 
macroglobulinaemia) 
Increased VLDL 
Chylomicrons 
Eruptive None 
Decreased 
remnant 
removal: 
Core lipid 
accumulation 
Dysbetalipo- 
proteinaemia 
(broad – beta 
disease) 
Hypothyroidism  Increased 
remnants, 
VLDL, 
chylomicrons, 
Abnormal apo E 
Planar 
(palmar) 
Tuberous 
Tubero 
eruptive 
disease 
Coronary  
peripheral  
vascular 
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PATHOPHYSIOLOGICAL CLASSIFICATION OF THE 
HYPERLIPIDAEMIA 
Table Continued… 
Disorders Mechanism 
Primary Secondary 
Lipoprotein 
Abnormalities 
Common 
Xanthomas 
Early 
Athero 
sclerosis 
Surface lipid 
Accumulation 
Decreased  
LDL removal 
LCAT deficiency  
Familial 
cholesterolaemia  
Familial defective  
Apo-B-100 
Liver disease 
Hypothyroidism  
Anorexia Nervosa 
Disc-shaped 
HDL 
LP-X 
Increased LDL 
Tendon 
Xanthomas 
Coronary  
Mechanisms  
unknown  
combined 
hyperlipid- 
aemias  
(multiple 
lipoprotein 
phenotypes) 
 Hypothyroidism 
Nephrotic Syndrome 
Glucocorticoid 
therapy 
Increased LDL 
and / or VLDL 
Increased Apo 
B 
Nil Coronary 
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GENETIC HYPERLIPOPROTEINEMIAS36 
Disorders 
Primary 
defect 
Plasma 
Lipoprotein 
pattern 
Genetic 
Mechanism 
Clinical 
findings 
Estimated 
Population 
Frequency 
Familial 
Hypercholesterolaemia 
LDL receptor 2a, 2b Autosomal 
dominant 
Palmar, Tuberous 
xanthomas, Premature 
atherosclerosis 
1-2/1000 
Polygenic 
Hypercholesterolaemia 
Unknown 2a, 2b Polygenic Palmar, Tendinous, 
xanthomas, premature 
atherosclerosis 
- 
Familial 
Hypercholesterolaemia 
Unknown 4,5 Autosomal 
dominant  
Nil 2/1000 
Familial combined 
Hyperlipidaemia 
Unknown 2a,2b,4,5 Autosomal 
dominant 
Eruptive xanthomas  
Premature 
atherosclerosis 
3-5/1000 
Familial dysbeta 
Lipoproteinaemia 
Apo E 3 Autosomal 
recessive 
Premature 
atherosclerosis  
Peripheral vascular 
disease 
1/10,000 
LPL deficiency Lipoprotein  
lipase 
1,4 Autosomal  
recessive 
Chylomicronaemia  
Syndrome, eruptive 
xanthomas 
- 
Rare 
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GENETIC HYPERLIPOPROTEINEMIAS36 
 Table Continued… 
Disorders 
Primary 
defect 
Plasma 
Lipoprotein 
pattern 
Genetic 
Mechanism 
Clinical 
findings 
Estimated 
Population 
Frequency 
Hepatic Lipase 
Deficiency 
Hepatic 
lipase 
- Unknown -  Rare 
Rare 
Apo C-II deficiency 
LCAT deficiency 
Lipid transfer protein 
deficiency 
apo C II  
Lecithin 
cholesterol 
acyl 
transferase 
Lipid 
transfer 
protein 
1,4 
- 
 
 
 
- 
Autosomal 
recessive 
Autosomal 
recessive 
Unknown 
Chylomicronaemia 
syndrome 
Corneal opacities 
Nephrotic syndrome, 
Renal failure 
- 
Rare 
 
 
 
 
 
 
 
 
 
 31
SECONDARY HYPERLIPOPROTEINEMIAS 
Plasma Lipoprotein Pattern 
Disease 
CHY IDL VLDL LDL 
CHY+ 
VLDL 
LDL+ 
VLDL 
Type 
Proposed 
Mechanism 
for hyper 
lipoproteine
mias 
Associated 
Abnormality 
of 
carbohydrate 
metabolism 
Endocrine 
Diabetes 
Mellitus, 
Severe, 
untreated 
+    +  1,5 Increased 
secretion of 
VLDL 
Insulin  
deficiency 
Moderate  + +  + + 2b,3,4,5 Decreased 
LPL&hence 
decreased 
catabolism 
of VLDL 
abd 
chy&VLDL 
Insulin 
resistance 
Corticostero
id therapy  
High dose  
Low dose: 
Cushing’s 
+  + + + + 1&5 
2a,2b,4 
Increased 
VLDL 
secretion in 
& 
accelerated 
conversion 
to LDL 
- 
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SECONDARY HYPERLIPOPROTEINEMIAS 
Table Continued… 
Plasma Lipoprotein Pattern Disease 
CHY IDL VLDL LDL CHY+ 
VLDL 
LDL+ 
VLDL 
Type 
Proposed  
Mechanism 
for hyper 
lipoproteinem
ias 
Associated  
Abnormality of  
carbohydrate  
metabolism 
Hypothyroidism  + + + + + 2a,2b,3,
4&5 
Decreased  
LPL activity 
Decreased 
receptor 
mediated 
LDL 
degradation 
Insulin deficiency 
or Insulin  
resistance 
Hypopituitarism  
(atellotic 
dwarfism) 
  +  +  4,5 Decreased 
LPL activity 
Decreased  
VLDL, 
&CHY 
degradation 
 
Acute Hepatitis  
(non fulminant) 
  +    4 Decreased 
LCAT 
- 
Hepatoma    +   2a Lack of 
feedback 
inhibition of 
hepatic chol 
synthesis by 
dietary chol 
- 
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SECONDARY HYPERLIPOPROTEINEMIAS 
Table Continued… 
Plasma Lipoprotein Pattern Disease 
CHY IDL VLDL LDL CHY+ 
VLDL 
LDL+ 
VLDL 
Type 
Proposed  
Mechanism 
for hyper 
lipoproteine
mias 
Associated  
Abnormality of  
carbohydrate  
metabolism 
Antihypertensive 
therapy (Thiazides, 
β-blockers)) 
 + +    3,4 ?Unopposed 
adrenergic  
activity 
- 
Iso retinal therapy 
 
  + + +  4,5 Unknown - 
Stress: emotional, Ml, 
burns, septicemia  
  + + +  4,5 Decreased 
LPL activity: 
Decreased 
catabolism,  
Increased 
secretion 
VLDL 
Insulin Resistance 
Acromegaly   +    4 Increased 
secretion of 
VLDL  
Insulin resistance 
Anorexia Nervosa   +    2a Decreased 
biliary 
secretion in 
of chol and 
bile acids 
- 
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SECONDARY HYPERLIPOPROTEINEMIAS 
Table Continued… 
Plasma Lipoprotein Pattern 
Disease 
CHY IDL VLDL LDL 
CHY+ 
VLDL 
LDL+ 
VLDL 
Type 
Proposed 
Mechanism for 
hyper 
lipoproteinemias 
Associated 
Abnormality of 
carbohydrate 
metabolism 
Estrogen or oral 
contraceptive 
therapy 
  +  +  4,5 Increased VLDL 
secretion in 
females 
genetically 
predisposed to 
hypertriglyceride
mia  
Insulin resistence 
Lipodystrophy 
(congenital or 
acquired) 
  +  +  4,5 Increased VLDL 
secretion 
Insulin resistance 
Von Gierke’s 
disease 
(glycogen 
storage disease, 
Type I) 
  +  +  4,5 Decreased LPL 
leads to 
decreased 
catabolism of 
VLDL&CHY 
Increased VLDL 
secretion 
Hypoglycemia with 
decreased  
Insulin secretion 
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SECONDARY HYPERLIPOPROTEINEMIAS 
Table Continued… 
Plasma Lipoprotein Pattern 
Disease 
CHY IDL VLDL LDL
CHY+
VLDL
LDL+ 
VLDL
Type 
Proposed 
Mechanism for 
hyper 
lipoproteinemias 
Associated 
Abnormality 
of 
carbohydrate
metabolism 
Non-
Endocrine  
Renal 
disease 
Nephrotic 
syndrome 
  + + + + 2a,2b,
4,5 
Increased 
secretion of  
VLDL increased 
secretion of 
VLDL Increased 
secretion form 
liver, decreased 
catabolism of 
VLDL 
- 
Uremia  + +  +  3,4,5 Decreased LPL 
activity  
Decreased 
catabolism of 
VLDL 
Insulin  
Resistance 
Alcoholism   +  +  4,5 Increased VLDL 
secretion 
 individuals 
genetically 
predisposed to 
hyper 
triglyceredimea 
- 
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SECONDARY HYPERLIPOPROTEINEMIAS 
Table Continued… 
Plasma Lipoprotein Pattern 
Disease 
CHY IDL VLDL LDL 
CHY+ 
VLDL 
LDL+ 
VLDL 
Type 
Proposed 
Mechanism for 
hyper 
lipoproteinemias 
Associated 
Abnormality of 
carbohydrate 
metabolism 
Dysglobulinemia + +  + +  1,2a, 
3,5 
IgG, IgM0 
antibodies to 
heparin 
chylomicron 
remenants  in 
VLDL resulting 
in low LPL 
activity and 
metabolism 
- 
Werner syndrome 
 
+    +  1,5 Unknown Insulin 
Resistance 
Acute 
intermittent 
porphyria 
   +  + 2a,2b Unknown - 
 
CHY – Chylomicron 
IDL – Intermediate Density Lipoprotein 
VDL – Very low Density Lipoprtoein 
LDL – Low Density Lipoprotein 
CHOL – Cholesterol 
LPL – Lipoprotein Lipase 
LCAT – Lecithin Cholesterol  Acyl Transferase 
 
 37
ASSAY PROCEDURES FOR SERUM LIPOPROTEINS 
 Ultra centrifugation of lipoproteins remains  the standard procedures for 
separation of lipoprotein fractions. 
 LIPOPROTEIN ELECTROPHORESIS is a simple procedure.   The 
electrophorosis can be carried  out on agarose sel.  However  there is a problem 
of automation.  In case of dyslipoproteinemia  difficulties are  faced in obtaining 
true hipoprotein separation and quantification. 
 SPECIFIC  PRECIPITAION OF LIPOPROTEINS  is based on the  
original work of Burstein.  Their simplicity and possibility of automation has 
made them widely used procedures. 
 High density lipoprotein (HDL) cholesterol can be determined by 
ultracentrifugation, electrophoresis, and precipitation based methods.  Several 
approaches for direct measurement of HDL-Cholesterol in the serum have been 
proposed  including the use of magnetically responsive particles such as 
polyanion metal combinations. 
 Lipid and lipoprotein measurements are usually performed  in the fating 
state.  But  recent evidences show that post-prandial lipaemia which includes 
Triglyceride rich, APO-B containing lipoproteins are atherogenic. 
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LIPID LEVELS IN INDIANS 
 
Category 
 
 
LDL – C   
(mg/dL) 
 
Cholesterol  
(mg/dL)          
 
Tryglycerides 
(mg/dL)  
 
Desirable    
 
 
< 100 
 
< 150 
 
< 150 
 
Borderline      
 
 
100 – 130 
 
150 - 200 
 
150 - 170 
 
High  
 
 
> 130 
 
> 200 
 
> 170 
 
( EnasEA – Why is there an epidemic of malignant CAD in young Indians ? 
Asian J Clin Cardiol 1998 ; 1 : 43 ) 
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LIPOPROTEIN (a) – Lp(a) is a predictor of macro vascular disease. 
 It was found that the level of Lp(a) was genetically determined by an 
autosomal dominant made of inheritance. 
 It is likely that Lp(a) is secreted directly by the liver and then associates 
with LDL.  LP(a)  has structural homology to LDL in its protein and lipid 
composition.   It has the capacity to bind to the fibrin  and to  membrance 
proteins of endothelial cells, monocytes and LP(a)  on the surface of fibrin  and 
cell membranes  favours finbrin and cholesterol deposition at sites of 
endothelial injury.  On the top of this pathogenesis of insufficient  activation of 
transforming  growth factor-Beta due to low plasmin activity, result in 
migration and proliferation of smooth muscle cells into the vascular intima53. 
 LP(a) is widely recognized as a biological marker for familial coronary 
artery diseas and high levels of LP(a) a can be considered to have the same 
importance as history of premature coronary artery disease in patients. 
 Three well known studies like PROLAM study, Framingham Heart  study 
and Quebec Cardiovascular  study demonstrated that LP(a) has independent  
risk factor for coronary artery disease but appears to have increased risk when 
associated with other lipid risk factors. 
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Lipoprotein (a) consists of LDL jointed by a single disulphide 
Bridge to apoprotein (a), which consist of the protease domain, kringle 
5 and a variable number of kringle 4 repeats of plasminogen 
 
Myocardial   infarction and cardiac death has been well correlated with 
the serum level of Lp(a).  Many studies also showed a linear relationship with 
the severty and extent of coronary artery involvement with the serum Lp(a) 
level. 
Evidence has emerged that male and female migrants from the Indian 
subcontinent have a higher mortality from Coronary Artery Disease than the 
native white population because of increased levels of Lp(a). 
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MANAGEMENT OF DYSLIPIDEMIA 
THERAPEUTIC LIFESTYLE CHANGES (TLC) DIET47,57 
 Initiation of the TLC diet as recommended by NCEP-ATP III has been 
estimated to lower LDL cholesterol levels by 10-20% 
Therapeutic lifestyle changes (TLC) Diet 
FOOD COMPOSITION RECOMMENDATION 
Total fat  saturated fat polyunsaturated 
fat Monounsaturated fat 
25-35% of total calories <7% of total 
calories up to 10% of total calories up to 
20% of total calories 
Carbohydrates 50-60% of total calories 
Fiber 20-30 gm/day 
Protein 15% of total calories 
Cholesterol <200 mg/day 
Total calories Sufficient to achieve or maintain 
desirable body weight. 
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PHYSICAL ACTIVITY 
Regular exercise that increases  heart rate 60-80%  of maximal peak heart 
rate for 30 minutes on all or most days of the week can raise HDL cholestezol 
levels up by 30% and can prevent or improve hypertension, insulin resistance 
and type 2 diabetes,  obesity, anxiety and depression70. 
 Regular exercise can also help smokers quit,  reduce the risk  of 
myocardial infarction and stroke by 50% or  more, reduce the risk of death  
following infarction 25% and improve functional capacity in patients with 
claudicating from peripheral arterial disease. 
 Recent studies indicate that physical activity does not need to be 
performed in a traditional structured exercise program to provide health benefits 
and that a lifestyle – based exercise program incorporating physical activity into 
daily living is effective at  improving  risk factors,  weight and long term 
cardiovascular  prognosis. (JAMA 1999: 281; 327-34) This can be 
accomplished by encouraging patients to use the stairs, walking whenever 
possible, gardening playing actively with children etc. 
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 Examples of moderate physical activity from the Surgeon General’s 
Report on Physical Activity and health (JAMA 1996: 276: 522)  
Include: 
• Washing and waxing a car or washing windows or floors for 45 minutes. 
• Gardening, dancing fast (social) or rating for 30 minutes 
• Walking 1 ¾ miles in 35 minutes (20min/mile) 
• Pushing a stroller  1 ½ miles or bicycling 5 miles in 30 minutes 
• Stair walking, shoveling snow or jumping rope for 15 minutes. 
The important factor is to accumulate at least 30 minutes of moderate  
Physical activity all or most days of the week, which can be split in three 10 
minutes blocks. 
 Health benefits may plateau at 3500 Kcal per week, the equivalent of 
moderately intense jogging or bicycling for one hour per day. 
 Patients with cardiovascular or respiratory disease  or sedentary patients 
with multiple coronary artery disease risk factors interested in participating in a 
vigorous exercise program should be considered  for stress testing. 
 
 
 44
 
WEIGHT CONTROL 
 Over weight  and obesity increase the risk of  all cause mortality and they 
increased morbidity  from hypertension,  dyslipidemia, type 2 diabetes, 
coronary artery disease, stroke, Gall bladder disease, osteo arthrosis,  sleep 
apnea,  respirators problems and cancers of endometrium, breast and colon56. 
 Weight control improves blood pressure, triglycerides, LDL and HDL 
cholesterol, blood glucose and hemoglobin AIc levels in type 2 diabetics. 
CLASSIFICATION OF OBESITY 
CATEGORY 
OBESITY CLASS 
BMI (BODY MASS 
INDEX) 
= wt in kg 
(ht in m)2 
Waist 
circumference 
Risk for type 2 diabetes, 
hypertension, CAD 
I 30 – 34.9 N 
↑ 
High 
Very high 
II 
 
35.0 – 39.9 N or ↑ Very high 
III 
 
≥ 40.0 N or ↑ Extremely high 
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WAIST - HIP RATIO 
 Waist circumference is the minimum circumference measured between 
costal margin and iliac crest and hip circumference is measured over the 
buttocks.  Waist – Hip circumference ratio more than 0.83 in females and 0.93 
in males were taken as abnormal. 
 The treatment of overweight and obesity may require the combination of  
• Dietary restriction – low carbohydrate and other ‘fad’ diets may facilitate 
early weight loss.  The best approach to diet is to eat smaller portions of a 
well rounded (TLC) diet. 
• Increased physical activity. 
• Behavior therapy. 
• Pharmacotherapy can be a useful adjunct to dietary restriction, increased 
physical activity and behaviour modifications but is unlikely to be 
effective as monotherapy.    The anti-obesity drugs approved by the FDA 
are sibutramine56 and orlistat.  (Lipase inhibitor) 
• Weight loss surgery - Gastric restriction or bypass should be reserved for 
motivated patients with extreme obesity (BMI ≥ 40 kg/m2) despite non-
surgical intervention. 
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AN OVERVIEW OF DRUG THERAPY 
FOR DYSLIPIDEMIA 
 For patients with dyslipidemia who require drug therapy the drug should 
be added to not substitute for diet therapy and lifestyle modification42. 
 
 EFFECTIVE CHOLESTEROL – LOWERING DRUGS59,63 
DRUG(USUAL 
STARTING DOSE / 
MAX) 
 
EFFECT ON 
LIPIDS 
 
COMMENTS 
HMG – COA Reductase Inhibitors (Statins) 
Rosuvastatin  
Atorvastatin74 
(10/80mg/d) 
Fluvastatin (20/80mg/d) 
Lovastatin(20/80 mg/d) 
Pravastatin68 (20/80mg/d) 
Simvastatin64(20/80mg/d) 
 
LDL – decrease by 
18-55% 
 
HDL – increase by  
5-20% 
TG- Decreases by  
7-30% 
Overwhelmingly the 
drug class of choice for 
elevated LDL levels. 
Adverse effects: 
1. Myopathy 
2. Elevation of liver 
transaminases.  
Monitoring to be done 
every six months. 
3. Fibrates and nicotinic 
acid should be used with 
caution in combination. 
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 EFFECTIVE CHOLESTEROL – LOWERING DRUGS59,63 
Table continued… 
DRUG(USUAL 
STARTING DOSE / 
MAX) 
 
EFFECT ON 
LIPIDS 
 
COMMENTS 
Nicotinic acid (Niacin)42 
Immediate release form 
(1.5-3/4.5g/day)  
Sustained – release form 
(1.2 /2g/day) 
Extended – release form 
(1-2/2g/day) 
 
LDL – decrease by  
5-25%  
HDL – increase by 
15-35%  
TG- Decreased by 
20-50% 
Useful in nearly all 
dyslipidemias. 
ADVERSE EFFECTS 
1. Flushing 
2. Hyperglycemia 
3. Hyperuricemia 
4. Gastritis 
5. Hepatotoxicity 
Bile acid sequestrants 
Colesevelam 
2.6 - 3.8/4.4g/d) 
Cholestyramine 
(4-16 / 24g/d) 
Colestipol 
(5-20/30g/d) 
LDL –decreases by  
15-30% 
HDL- increases by 3-
5% 
TG-usually not 
affected 
may actually increase 
Useful in moderate 
hypercholesterolemia, 
younger patients with 
elevated LDL cholesterol 
and women with elevated 
LDL cholesterol, who are 
considering pregnancy?  
Useful as adjunctive 
therapy with statins. 
ADVERSE EFFECTS 
1. Gastritis 
2. Decreased absorption 
of several drugs. 
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 EFFECTIVE CHOLESTEROL – LOWERING DRUGS59,63 
Table continued… 
DRUG(USUAL 
STARTING DOSE / 
MAX) 
 
EFFECT ON 
LIPIDS 
 
COMMENTS 
Fibric acid Derivatives 
Gemfibrozil            
(600mg bid)       
Fenofibrate               
(160 mg/d)    
Clofibrate               
(1000 mg bid)  
LDL – decreases by 
 5-20%  
HDL – increases by  
10-35%  
TG- Decreased by  
20-50% 
Major uses: 
1. Hypertriglyceridemia 
2. Atherogenic 
dyslipidemia 
(Especially type ‘z’ 
diabeties) 
ADVERSE EFFECTS 
1. Dyspepsia 
2. Gastritis 
3. Cholesterol Gall stones 
4. Myopathy 
Cholesterol absorption inhibitor 
Ezetimibe (10mg/day) LDL –decreases by 
18% 
HDL- increases by 
1% 
TG-decreases by 8%    
                       
Used as an adjunct to 
statins when further LDL 
lowering is required.     
Not recommended in 
moderate or severe 
hepatic in sufficiency.    
ADVERSE EFFECTS: 
Gastritis.                   
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DRUG THERAPY BASED ON LIPID PROFILE 
PROFILE TREATMENT48 COMMENTS 
(A) High LDL, Normal TG (Type II a)      
LDL ≥ 190 
TG < 150 
 
Mono therapy statin 
combination: 
Statin + ezetimibe,  
Statin + niacin, 
Statin + biteacid       
Sequestrants         
Bile acid sequestrant is 
preferred as 
monotherapy if liver 
disease is present. 
 
LDL ; 160 – 190 
TG : 150 - 400 
Monotherapy : Statin 
Alternative:  Niacin, 
ezetimibe, Bile acid 
sequestrants 
Statin, niacin, Bile acid 
sequestrants have 
process long term.  
Safety profiles 
(B) Mixed Hyperlipidemia (↑LDL, ↓ TG) Type II 
LDL : 160 – 190 
TG : 150 - 400 
Monotherapy : Statin 
Alternative : Niacin, 
Fibric acid derivative, 
ezetimibe. 
COMBINATION: 
1. Statin + niacin 
2. Statin + fibric acid 
derivative 
3. Statin + ezetimibe 
4. Fibric acid derivated 
+bile acid sequestrant. 
Niacin reduced 
myocardial infarction 
by 27% in the coronary 
drug project. 
Gemfibrozil reduced 
coronary artery disease 
by 34% in the Hesink 
Heart study. 
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DRUG THERAPY BASED ON LIPID PROFILE 
 Table continued… 
PROFILE  TREATMENT48        COMMENTS 
(C) Hyper Triglyceridemia (Type IV, Type V) 
LDL < 130                 
TG > 400 
 
Monotherapy:            
Niacin, Fibric acid 
derivations, fish oils  
COMBINATION:         
1. Fibric acid 
derivatives + fish oils55. 
2. Niacin + fish oils. 
3. Fibric acid 
derivatives + Niacin 
1. Fish oils may be used  
    as adjunctive therapy. 
2. Treat to  decrease the  
    risk of pancreatitis. 
 
(D) Isolated low HDL (HDL < 40 MG/DL)49 
LDL < 130    
TG < 150         
 
Monotherapy:        
1. Niacin  
2. Fibric acid 
derivatives  
3. Statin                
COMBINATION:         
1. Niacin + statin 
Niacin + fibric acid 
derivatives. 
1. Low HDL greatly 
increase coronary artery 
disease risk even in the 
absence of elevated 
LDL.  
2. Gemfibrozil reduced 
myocardial infarction 
(or) coronary death by 
22% (VA-HIT study)       
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MATERIALS AND METHODS 
 
 The study was conducted at the intensive coronary care unit and medical 
wards of Tirunelveli Medical College Hospital, Tirunelveli during the period of 
August 2004 to August 2005. 
• Hundred patients who were admitted with a confirmed diagnosis of acute 
myocardial infarction were enrolled in the study. 
• The diagnosis of acute  myocardial infarction was made if patients had 
ischemic type chest pain for ≥ 30 minutes with evidence of ST – segment 
elevation of ≥ 1 mm in two anatomically contiguous leads on the  ECG or 
the appearance of a new left bundle branch block. 
• Patients who had symptoms suggestive of acute myocardial infarction but 
did not meet the ECG diagnostic criteria, needed to have serum creatinine 
– kinase MB levels that were more than twice the upper limit of normal. 
• Exclusion criteria were the following  
1. Symptoms suggestive of acute myocardial infarction ≥ 12 hours. 
2. Hospital stays of < 4 days. 
3. Already receiving lipid – lowering medications. 
• All the patients were followed from the day of admission to the day of 
discharge. 
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LIPID MEASUREMENTS 
 
 Besides clinically examination and routine investigation, the serum lipid 
profile was measured within the first 24 hours of the onset of symptoms of 
myocardial infarction and again at day 4 post myocardial infarction. 
 The serum total cholesterol, triglyceride levels were measured by 
colorimetric test and HDL cholesterol is measured by precipitation assay. 
 The LDL cholesterol value was calculated by using the Friedewald 
formula. 
 LDL cholesterol = total cholesterol –HDL cholesterol – (triglyceride/5) 
 The cholesterol ratios then were calculated by using the total cholesterol / 
HDL cholesterol and LDL cholesterol / HDL cholesterol ratios.  All the blood 
samples were 12 hours fasting samples. 
STATISTICAL ANALYSIS 
 Continuous variables were expressed as the mean ± standard deviation 
(SD) and the categoric variables were expressed as a percentage.  The 
student’s‘t’ test was used to compare lipid values and ratios between day 1 post 
M I and day 4 post M I.  A two tailed ‘P’ value of < 0.05 was considered to be 
significant. 
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OBSERVATION AND ANALYSIS 
 
1. Eighty one percent (81%) of the patients studied were men. 
2. Hypertension was present in Thirty –three (33%) percent of the patients 
studied. 
3. Twenty nine (29%) percent of the patients studied were diabetic. 
4. Thirty seven (37%) percent of the patients studied were smokers. 
5. Sixteen (16%) percent of the patients had family history of coronary 
artery disease. 
6. Out of the hundred patients studied, non ST elevation myocardial 
infarction was diagnosed in twenty (20%) patients. 
7. Eighty (80%) of the patients studied were diagnosed to have ST elevation 
myocardial infarction. 
8. Sixteen (16%) of the patients studied were obese. 
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CLINICAL CHARACTERISTICS OF THE STUDY POPULATION 
 
Total number of cases studied = 100 
Sl.No CHARACTERISTICS 
PATIENTS No 
(Percentage) 
 
1. 
 
Hypertension 
 
33% 
 
2. 
 
Diabetic mellitus 
 
29% 
 
3. 
 
Smokers 
 
37% 
 
4. 
 
Positive family history 
 
16% 
 
5. 
 
Non ST elevation Myocardial infarction
 
20% 
 
6. 
 
ST elevation myocardial infarction 
 
80% 
 
7. 
 
Obesity 
 
16% 
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OBSERVATION IN LIPID PROFILE 
 
1. All serum lipid levels changed significantly between day 1 post 
myocardial infarction (within 24 hours) and day 4 post myocardial 
infarction. 
2. On day 1 post myocardial infarction the mean total cholesterol value is 
190.10. 
3. On day 4 post myocardial infarction, the mean total cholesterol value is   
172.50. 
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190.1
172.5
160
165
170
175
180
185
190
195
D1 D2
MEAN CHOLESTEROL VALUES
MEAN CHOLESTEROL
VALUES
 
 
 
 
Mean Cholesterol Value – D1 
Post Myocardial infarction  = 190.10 
 Mean Cholesterol Value – D4 
Post Myocardial infarction  = 172.50 
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OBSERVATION IN LIPID PROFILE 
 
4. On day 1 of post – myocardial infarction, the mean triglyceride value was 
124.98. 
5. On day 4 of post – myocardial infarction, the mean triglyceride value was 
143.22 
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124.98
143.22
115
120
125
130
135
140
145
D1 D4
MEAN TRIGLYCERIDE VALUE
MEAN
TRIGLYCERIDEVALUE
 
 
 
 
Day – 1 Post Myocardial Infarction 
Mean TriglycerideValue = 124.98 
Day – 4 Post Myocardial Infarction 
Mean TriglycerideValue = 143.22 
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OBSERVATION IN LIPID PROFILE 
 
6. Regarding the Cholesterol ratios, the ratio at total cholesterol to High 
Density Lipo protein cholesterol (Cholesterol / HDL ratio) on day – 1  
post myocardial infarction and day 4 post myocardial infarction were 
4.300 and 4.380 respectively. 
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4.3
4.38
4.26
4.28
4.3
4.32
4.34
4.36
4.38
D1 D4
CHO/HDL RATIO
CHO/HDL RATIO
 
 
 
Day – 1 Cholesterol / HDL Ratio = 4.300 
Day – 4 Cholesterol / HDL Ratio = 4.380 
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OBSERVATION IN LIPID PROFILE 
 
7. The ratio at low density lipoprotein cholesterol to high density lipoprotein 
cholesterol (LDL/HDL ratios) on day – 1 post myocardial infarction and 
day- 4 post myocardial infarction were 2.710 and 2.690 respectively. 
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2.71
2.69
2.68
2.685
2.69
2.695
2.7
2.705
2.71
D1 D4
LDL/HDL RATIO
LDL/HDL RATIO
 
 
 
 
Day - 1 LDL / HDL Ratio = 2.710 
Day - 4 LDL / HDL Ratio = 2.690 
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COMPARISON OF THE SERUM LIPID VALUES AND RATIOS 
BETWEEN WITHIN 24 HOURS OF MYOCARDIAL INFARCTION 
AND DAY-4 POST MYOCARDIAL INFARCTION 
  
Serum lipids 
Within 24hrs of 
Myocardial infarction
Day-4 post 
Myocardial 
infarction 
‘Z’ and ‘P’ 
Values 
Total cholesterol 
(mg/dl) 
190.10±25.75 172.50±27.05 6.33 
Triglycerides (mg/dl) 
 
124.98±38.35 143.22±35.64 4.02 
Total cholesterol 
HDL cholesterol ratio 
4.30±0.36 4.38±0.36 0.33 
LDL cholesterol 
HDL cholesterol ratio 
2.71±0.40 2.69±0.38 0.06 
 
The values are expressed as mean ± standard deviation. 
 If ‘z’ is > 1.96 and if ‘P’ is < 0.05 then the change is significant. 
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DISCUSSION 
 
 Many studies in the past few decades have shown that acute myocardial 
infarction results in a significant decrease in the serum levels of total 
cholesterol, LDL cholesterol and HDL cholesterol 5,7. 
 The acceptable time for the measurement of plasma lipids after an acute 
myocardial infarction is within 24 hours after the onset of symptoms and the 
plasma lipid levels measured beyond 24 hours are mostly considered to be 
invalid 6. 
 The post myocardial infarction decline in serum cholesterol occurs 
because of the acute – phase response19, and is of greatest extent by days 4 to 
day 5 post – myocardial  infarction9. 
 Acute myocardial infarction like any other tissue injury, initiates various 
local and systemic reactions20. 
 The local response includes vasodilation, leucocyte infiltration and 
chemotaxis, monocyte and macrophase  activation and cytokine release22. 
 The cytokines act on the systemic targets, including the liver to generate 
changes in the concentration of various heterogenous plasma proteins, 
collectively known as acute – phase reactants including lipoproteins23,24. 
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 By day 4 to 5 post – myocardial infarction, there is a  significant  
decrease in the serum concentrations of apoprotein A-1 and apoprotein-B 
reflecting the maximum decrease in the serum cholesterol level by the time25. 
 While the serum cholesterol level decreases after an acute myocardial 
infarction, the serum triglyceride level increases. 
 This paradoxical  rise in serum triglycerides is due to and increase  in 
serum – C reactive  protein level which  may increase to levels that are  several 
hundred – fold higher than baseline 4 days after and myocardial infarction24. 
 The C- reactive protein binds selectively with very LDL and interferes 
with its catabolism thereby increasing the serum triglyceride concentration26. 
 The magnitude of the decrease in serum cholesterol level after an 
myocardial  infarction is positively  correlated  with the infarct size and is not 
dependent on the patients age or sex,  the development of arrhythmias, the 
medications being received or the development of heart failure28. 
 The decrease in serum cholesterol levels after acute myocardial infarction 
is transient and these levels gradually return to the baseline pre-myocardial 
infarction values in 2 to 3 months6. 
 Therefore most experts recommend measuring the serum cholesterol 
levels within the first 24 hours after the onset of an acute infarction18 (or) 
otherwise deferring measurement until 2 to 3 months after the myocardial 
infarction11. 
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 However deferring the measurement of serum cholesterol levels in  
patients whose cholesterol levels were not determined with in the first 24 hours 
after the onset of acute infarction can lead to a delay in initiating the appropriate 
cholesterol lowering therapy for the secondary prevention of future coronary 
events71. 
 The National cholesterol Education program guidelines recommend using 
the absolute values of total cholesterol, LDL cholesterol and HDL cholesterol as 
determined of the cholesterol risk and the therapeutic goals have been set forth 
using these absolute serum cholesterol levels. 
 These guidelines emphasized the issue stating that LDL cholesterol and 
HDL cholesterol are independent risk factors requiring individual attention. 
 Several large – scale epidemiologic studies have shown that the total 
cholesterol / HDL cholesterol ratio are also strong predictors of  coronary artery 
disease  events because these ratios sum up the  importance of both the total 
cholesterol or the LDL cholesterol and HDL cholesterol  collectively. 
 The study has shows that in certain situations in which the plasma  
cholesterol levels are not measured within the first 24 hours after the onset of 
acute myocardial infarction,  cholesterol ratios determined from the serum 
cholesterol measurements taken after 24 hours of the  onset of acute infarction 
could be used reliably for cholesterol risk assessment9. 
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 Because at day 4 post-myocardial infarction when the absolute values of 
serum total cholesterol.  Significantly decreased from the baseline value at  day 
one post – infarction, the  ratios at total cholesterol to HDL cholesterol and LDL 
cholesterol to HDL cholesterol remained unchanged. 
 The ratios of total cholesterol to HDL cholesterol and LDL cholesterol to 
HDL cholesterol that have been reported to correlate with the development of 
acute coronary events are > 4.3 and > 2.7 respectively. 
 In the study the mean (± standard deviation) total cholesterol to HDL 
cholesterol ratio was 4.30 ±  0.36 at day one.  Post myocardial infarction and 
did not change significantly at day – 4 posts – infarction. 
 These findings suggest that the cholesterol ratios could be used to 
determine cholesterol risk in patients who experienced acute myocardial 
infarctions and may have an advantage in situations in which the absolute total 
and fractionated cholesterol levels are longer applicable because of the effect of 
the acute myocardial infarction.  (Beyond 24 hours after the onset of acute 
myocardial infarction)10. 
 The results observed in the studies of acute myocardial infarction on 
cholesterol and cholesterol ratios like Jackson R et al10, chamsi-Pasha et al11, 
Brugada R et al6, Heldenberg D et al7 and PyFe T et al9 are consistent with the 
present study.  
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CONCLUSION 
 
• Following acute myocardial infarction the total serum cholesterol level 
falls significantly and the triglyceride level rises significantly. 
• Therefore measurement of absolute levels of serum cholesterol and 
triglycerides following acute myocardial infarction are not valid in 
risk assessment 24 hours after infarction. 
• But acute myocardial infarction does not affect the cholesterol ratios. 
(Cholesterol / HDL and LDL / HDL cholesterol ratios) even 24 hours 
after infarction.   
• Therefore following acute myocardial infarction, the cholesterol ratios 
are valid and very useful in risk assessment.   
• Treatment for hypercholesterolemia may be done on the basis of these 
cholesterol ratios in situations in which absolute levels of serum  
cholesterol and triglycerides are not valid.  (After 24 hours of onset of 
acute myocardial infarction). 
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SUMMARY 
 
 A study of 100 patients admitted with acute myocardial infarctions has 
revealed that, acute myocardial infarction significantly reduces the total serum 
cholesterol levels and increases the serum triglyceride levels.   But the acute 
myocardial infarction has no significant effect on the cholesterol ratios (LDL 
cholesterol / HDL cholesterol ratios and cholesterol / HDL cholesterol ratio).  
So after 24 hours of acute myocardial infarction assessment of cholesterol ratios 
will be more appropriate than assessing total cholesterol levels. 
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KEY NOTES FOR MASTER CHART 
 
Sl.No  - Serial Number 
IP No  - In Patient number 
SE Status - Socio Economic Status 
dur’n  - duration 
hrs  - hours 
DM  - Diabetes mellitus 
HT  - Hypertension 
STEMI - ST Elevation myocardial infarction 
NSTEMI - Non ST Elevation Myocardial Infarction 
↑  - Increased 
MI  -  Myocardial Infarction 
CHOL  - Cholesterol 
TGL  - Triglyceride 
HDL  - High Density Lipoprotein 
LDL  -  Low  Density Lipoprotein 
 
 
 
 X
BIBLIOGRAPHY 
 
1. Sacks FM, PFeffer MA, Moye  LA, et al .  The effect of pravastatin on 
coronary events after myocardial infarction in patients with average 
cholesterol levels.  Cholesterol and Recurrent Events Trial investigators.  
N Engl J Med 1996: 335 : 1001 – 1009. 
2. Scandinavian Simvastatin Survival study Group.  Randomized trial of 
cholesterol lowering in 4444 patients with coronary heart disease; the 
Scandinavian simvastatin Survival study (4s).  Lancet 1994 ; 344 : 1383 – 
1389. 
3.  Long term Intervention with Pravastatin in Ischemic Disease (LIPID) 
study Group. Prevention of cardiovascular events and death with 
pravastatin in patients with coronary artery heart disease and a broad 
range of initial cholesterol levels.  NEngl J Med 1998 ; 339 : 1349 – 
1357. 
4. Castelli WP.Epidemiology of coronary heart disease; the Framingham 
study.  Am J Med 1984 : 27 : 4 – 12. 
5. Ryder RE, Hayes TM, Mulligan IP, et al.  How soon after myocardial 
infarction should plasma lipid values be assessed? BMJ 1984 ; 289 ; 1651 
– 1653. 
 XI
6. Brugada R, Wenger NK, Jacobson TA, et al Changes in Plasma 
cholesterol levels after hospitalization for acute coronary events.   
Cardiology 1996 ; 87 : 194 – 199. 
7. Heldenberg D, Rubinstein A, Levtor O,  et al Serum lipids and 
lipoprotein  concentrations during the acute phase of myocardial 
infarction.   Atherosclerosis 1980 ; 35 : 433 – 437. 
8. Watson WC, Buchanon KD, Dickon C, Serum cholesterol levels after 
myocardial infarction Br J Med  1963 ; 2 : 709 – 712. 
9. Pyfe T, Baxter RH, Cochran DM, et al.  Plasma lipid changes after 
myocardial infarction, Lancet 1971 ; 2 :  997 – 1001. 
10. Jackson R, Scragg R, Marshall R, et al.  Changes in    serum lipid 
concentrations during first 24 hours after myocardial infarction.  BMJ 
1987 ; 294 : 1588 – 1589. 
11. Chamsi – Pasha H, Taylor RJ, Mc Dowell D, et al.  Plasma lipids, when 
to measure after myocardial infarction?  Br J Clin Pract 1989 : 43 : 447 - 
450. 
12. Linn S, Tulwood R, Caroll M, et al.  serum total cholesterol : HDL  
cholesterol ratios in US white and black adults by selected demographic 
and socio economic variables ( HANES II ). 
American J Pubic Health  1991 ; 81 ; 1038 – 1043. 
 XII
13. Friedewald WT, Levy RI, Fredrickson DS, Estimation of the 
concentration of low – density lipoprotein cholesterol in plasma, without 
the use of the preparative  ultra centrifuge. Clin Chem 1972 :18;499-502   
14. Ronnemaa T, Viikari J, Irjalak, et al.  Marked  decrease in serum HDL 
cholesterol level during acute myocardial infarction.  Acta Med Scand 
1980 ; 207 : 161 – 166. 
15. Biorck G, Blomquist G,  Sievers J.  Cholesterol values in patients  with 
myocardial infarction and in a normal control group.  Acta Med Scand 
1957 ; 156 ; 493 – 497. 
16. Dodds C, mills GL, Influence of myocardial infarction on plasma – 
lipoprotein concentration.  Lancet 1959 : 1 : 1160 – 1163. 
17. Gore JM, Goldbers RJ, Matsumoto AS, et al.  Validity of   serum total 
cholesterol level obtained within 24 hours. American  J Cardial 1984 : 54 
: 722 – 725. 
18. Sewdarsen M, Vythilingam S, Jialal J, et al.  Plasma lipids can be reliably  
assessed within 24 hours after acute myocardial infarction.                                              
Post Grad Med J 1988 : 64 : 352 – 356. 
19. Rosenson RS.  Myocardial injury : the acute phase response and 
lipoprotein  metabolism.  JAm coll cardial 1993 ; 22 ; 933 – 940. 
20. Werner M.Serum protein changes during the acute phase reaction.  Clin 
Chim Acta 1969 : 25 : 299 – 305. 
 XIII
21. Logon RW, Murdoch WR, Blood – levels of hydrocortisone, 
transaminases  and cholesterol after myocardial infarction.  Lancet 1966 ; 
2 : 521 – 524. 
22. Smith SJ, Bos G, Essevaveld MR, et al.  Acute phase proteins from the 
liver and enzymes from myocardial infarction a quantitative relationship.  
Clin Chim Acta 1977 ; 81 ; 75 – 85. 
23. Harrison SP.  Pre-albumin and  C-reactive protein after acute myocardial 
infarction Med Lab Sc; 1987 ; 44 ; 15 – 19. 
24. Rowe IF, Soutar AK, tranyner IM, et al.  Human C-reactive protein binds 
very low density lipoprotein.  Clin Exp.  Immunol 1984 : 58 : 237 – 244. 
25. Avogar OP, Bon GB, Cazzolato G  et al.  Variations in apolipoproteins B 
and A-1 during the course of myocardial infarction Eur J Clin Invest 1978 
; 8 ; 121 – 129. 
26. Mundy GR, Mc Pherson  DG.  Variations in serum cholesterol levels 
after myocardial infarction Med J Aust 1973 ; 1 ; 278 –282. 
27. Enger S, Ritland S. Serum lipoprotein pattern in myocardial infarction.  
Acta Med Scand 1970 ; 187 ; 367 – 371. 
28. Ahnve S, Angelin B, Edhag O, et al.   Early determination of serum lipid 
and apolipoproteins  in acute myocardial infarction : possibility for 
immediate intervention.  J Intern Med 1989 ; 226 ; 297 – 301. 
 XIV
29. Fonarow GC, Gawlinsk.    A, Rationate and design of the Cardiac  
Hospitalization Atherosclerosis Management  Program at the University 
of California Les Angeles.  AM J Cardiol 2000 ; 85(suppl) ; 10A – 17A. 
30. National cholesterol Education Program, Second report of the Export 
Panel on Detection.  Evaluation and Treatment of High Blood Cholesterol 
in Adults (Adult Treatment Panel II).  Circulation 1994 ; 89 ; 1333 – 
1445. 
31. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at 
risk of ischemic events (CAPRIE).  Lancet 1996 ; 348 ; 1329 – 39. 
32. American Diabetes  Association.  Standards of medical care for patients 
with diabetes mellitus.  Diabetes care 2000 ; 23 (Suppl-I) S-32 – S-42. 
33. American Diabetes  association.  Management of dyslipidemia in adults 
with diabetes.  Diabetes care 2003 ; 26 ; S-83 – S-86. 
34. Antiplatelet Trialist’s collaboration.  Secondary preventrion of vascular 
disease by prolonged antiplatelet treatment.  Br Med J (clin Res Ed) 1988 
; 296 ; 320 – 31. 
35. Antiplatelet Trialist’s collaboration.  Prevention of death, myocardial 
infarction and stroke by prolonged antiplatelet therapy in various 
categories of patients BMJ  1994 ; 308 ; 81 – 106. 
36. Ballantyne CM, Hyperlipoproteinemias.  Rakel RE, Bope e T, Conn’s 
current therapy 2002, Philadelphia ; W.B.Saunders 2002 ; 572 – 577. 
 XV
37. Ballantyne CM, Rangara ; GR.  The Evolving  role of high – density 
lipoprotein in reducing cardiovascular risk.  Prev Cardiol 2001 ; 4 ; 65 – 
72. 
38. Ballantyne CM, Olsson AG, Cook TJ et al.  Influence of low high - 
density lipoprotein cholesterol and elevated triglyceride on coronary heart 
disease events and  response to simvastatin therapy if 45.  Circulation 
2001 ; 104 ; 3046 – 3051. 
39. Ballantyne CM, Andrews  TC, Hsia J4, et al.  Correlation of non HDL 
cholesterol with Apolipoprotein B.  Am J Cardiol 2001 ; 88 ; 265 – 269. 
40. Blair SN, Good year NN, Gibbons LW, cooper KH.  Physical fitness and 
incidence of hypertension in healthy normotensive men and women.  
JAMA 1984 ; 252 ; 487 – 490. 
41. Burr ML, Fehily AM, Gilbert JF et al.  Diet and  reinfarction trial 
(DART) Lancet 1989 ; 2 ; 757 – 61. 
42. Canner PL, berge KG, Wenger NK, et al.  Fifteen year mortality in 
coronary Drug Project patients.  Long term benefit with niacin.  J AM 
Coll Cardiol 1986 ; 8 ; 1245-55. 
43. Dietary Supplementation with n-3 PUFA and Vitamin E after myocardial 
infarction.  Lancet 1999 ; 354 ; 447 – 55. 
 XVI
44. Down JR, Clear Field M, Weis S et al.  Primary prevention of acute 
coronary events with lovastatin in men and women.  With average 
cholesterol levels.  JAMA 1998 ; 279 ; 1615 – 22. 
45. Farmer JA.  Gotto AM Jr. Dyslipidemia and the vulnerable plaque.   
Prognosis of cardiovascular disease. 2002 ; 44 ; 415 – 528. 
46. Farmer – JA.  Pleitrophic effects of statins.  Current  Atherosclerosis 
Report. 2000 ; 2 ; 208 – 217. 
47. Fedder Do, Koro CE, L’Stalien G3.  New national Cholesterol Education 
Program III  guidelines for primary prevention lipid lowering drug 
therapy.  Circulation 2002 ; 105 ; 152 – 156. 
48. Gotto AM Jr.  Treating hyperlipidemia looking  forward.  Clin Cardiol 
2003 ; 26 (121-128) 
49. Gotto AM Jr.  HDL cholesterol and triglycerides as therapeutic targets for 
preventing and treating coronary artery disease AM heart J 2002 ; 144 ; 
S-33 to S-42. 
50. Gotto AM Jr. Statins and C-reactive protein, considering a novel marker 
of cardiovascular  risk.  Orev cardiol 2002 ; 5 ; 200 – 203. 
51. Gotto AM Jr.  Lipid management in diabetic patients.   Lesson from 
prevention trials.  AM J Med 2002 ; 112 (Suppl 8-A) ; 195 – 265. 
52. Gotto AM Jr, Management  of dyslipidemia AM J Med 2002 ; 112(Suppl 
8-A) ; 10 S – 18 S.  
 XVII
53. Gotto A,  Pawnall H, Manual of lipid disorders, 3rd edn, Philadelphia PA; 
Lippincott Williams & Wilkins ; 2003 ; 482 PP. 
54. Haffrer SM ; Metabolic syndrome,  diabetes and coronary heart disease 
Int J Clin Pract Suppl 2002 ; 132 ; 31 – 37. 
55. Huf B,  Bronner L, Willet Wa et al.  Fish and omega –3 fatty acid intake 
and risk of coronary  heart disease in women.  JAMA 2002 ;287;1815-21. 
56. James WPF, Astrup A, Finer N et al.  Effect of sibutramine on weight 
maintenance after weight loss.  A randomized trial.  Lancet  2000 ; 356 ; 
2119 – 2125. 
57. Jones PH, Diet and Pharmacologic therapy of obesity to modify  
atherosclerosis.  Curr Atherosclerosis Report 2000 ; 2 ; 314 – 320. 
58. Knnop RH, Drug treatment of lipid disorders  N Engl J Med 1999 ; 341 ; 
498 – 511. 
59. Long term effectiveness and safety of pravastatin in 9014 patients with 
coronary heart disease and average cholesterol values.  Lancet 2002 ; 359 
; 1379 –87. 
60. Maron DJ, Fazio S, Linton MF.  Current perspectively on statins.  
Circulation 2000 ; 101 ; 207 –213. 
61. Paternak RC, Smith SC Jr, Bairey-Merz CN et al.  ACC/AHA/NHLB1 
Clinical advisory on the use and safety of statins JAm Coll Cardiol 2002 ; 
40 ; 567 – 572. 
 XVIII
62. Pearson TA, Blair SN, Daniels SR et al.  AHA guidelines for primary 
prevention of cardiovascular disease 2005 update circulation 2002 ; 106 ; 
388 – 391. 
63. The long-Term Intervention with pravastatin in Ischemic Disease (LIPID) 
study group.  N Engl J med 1998 ; 339 ; 1349 – 57. 
64. Randomized trial of cholesterol lowering in 4444 patients with coronary 
heart disease.   The Scandinavian simvastatin  survival study.  (4S) 
Lancet 1994 ; 344 ; 1389-9. 
65. Rifa: N, Ridker PM.  Inflammatory markers and coronary heart disease.  
Curr opin lipidol 2002 ; 13 ; 383 – 389. 
66. Robins SJ, Colling D, Wittes JT et al.  Relation of gemfibrozil treatment 
and lipid levels with major coronary events.  JAMA 2001 ;285;1585 – 91. 
67. Sacks FM, Pfetter MA, Moye LA et al.  The effect of pravastatin  on 
coronary events after myocardial infarction in patients with average 
cholesterol levels N Engl J Med 1996 ; 335 ; 1001 – 9. 
68. Shepherd J, Cobba SM, Ford I et al.  Prevention of coronary artery 
disease with pravastatin in men with  hypercholesterolemia N Engl J 
Med.  1995 ; 333 ; 1301 – 7. 
69. Smith SC Jr, Blair SN, Bonow  RO et al.  AHA guidelines  for preventing 
death in patients with atherosclerotic coronary disease .  Cardiology 
circulation 2001 ; 104 ; 1577 – 1579. 
 XIX
70. Smith SC Jr, Greenland P, Grundy SM.  Identifying the high risk patient 
for primary prevention ;  executive summary.  Circulation 2000 ; 101 ; 
111 – 116. 
71. The lipid Research Clinics coronary primary prevention Trial results.  
Reduction in  incidence of coronary heart disease.  JAMA 1984 ; 251 ; 
351 – 64. 
72. Lipid Research clinics coronary primary prevention Trial results.  3 AMA 
1984 ; 251 ; 365 – 74. 
73. Third Report of the National cholesterol Education program (NCEP) 
expert panel on detection, evaluation and treatment of  
hypercholesterolemia in adults.  (ATP III)  Final report.  Circulation 2002 
; 106 ; 3143 – 421. 
74. Waters DD, Schwartz G5, Olsson AG et al, Effects of atorvastatin on 
stroke in patients with unstable Angina.  A myocardial ischemia 
Reduction with Aggressive cholesterol lowering (MIRACL) Sub study 
circulation 2002 ; 106 ; 1690 – 1695. 
75. Xydakis AM, Ballantyne CM, Combination therapy  for combined 
dyslipidemia.  American Journal of cardiology 2002 ; 90 ; 21K – 29K. 
76. Yusuf S, Wittes J, Friedman L.  Overview of results of randomized 
clinical trials  in heart disease.  JAMA 1988 ; 260 ; 2088 – 93. 
 XX
77. Davies  MJ A Macro  and Microview of coronary cardiovascular insult in 
ischemic heart disease circulation 1990 ; 82 – 86. 
78. Ross, R.  The pathogenesis of atherosclerosis and update.  NEJM 314 ; 
488 , 1986. 
79. Yancy WS   Jr, Westman EC, Frencin PA, Califf RM, Diets  and clinical 
coronary events.  Circulation 2003 ; 107 ; 10 – 16. 
 
 I
PROFORMA 
NAME    : 
AGE     : 
SEX     : 
OCCUPATION   : 
SOCIO ECONOMIC STATUS : 
EDUCATIONAL STATUS : 
DATE OF ADMISSION  : 
PRESENTING SYMPTOMS : Y(Yes) N(No) 
1. Chest pain 
 Time of onset 
2. Angina equivalents   
 (Specify) 
PAST HISTORY 
 H/O CAHD 
  HT 
  DM 
 STROKE 
 HYPERLIPIDEMIA 
 
 II
PERSONAL HISTORY: 
 DIET 
 SMOKING 
 ALCOHOL 
 ORAL CONTRACEPTIVES 
 OBSTETRIC  HISTORY 
 
FAMILY HISTORY 
GENERAL EXAMINATION 
GENERAL APPEARANCE  Comfortable  
      Anxious 
      Yes  No 
CYANOSIS 
CLUBBING 
PEDAL OEDEMA 
ANAEMIA 
COLD CLAMMY SKIN 
 
 
 
 III
 
VITAL SIGNS 
 Pulse  -  Rate 
  Rhythm 
    Volume 
    Vessel wall thickness 
    Peripheral pulses 
 BP  -  Upper limb 
    Lower limb 
CVS Examinations 
1. JVP 
2. Apical impulse 
3. Parasternal Pulsations 
4. Heart sounds – S1 S2 –  Normal intensity  
(or) 
     Muffled 
      (or) 
     Loud intensity 
5. Additional  heart sounds 
6. Murmur 
7. Pericardial Rub. 
 IV
RS Examination : Crackles   Wheeze 
 
INVESTIGATIONS 
ECG in 15 leads 
Cardiac Enzyme CPK-MB 0 hours 6-12hours > 12 hours 
   SGOT 
Hb% Blood Glucose 
  Urea 
 Serum Creatinine 
  Electrolytes 
Sl.No LIPID PROFILE Within 24 hours of M 1 Day 4 post M 1 
 
1. 
2. 
3. 
4. 
5. 
6. 
Total Cholesterol 
LDL cholesterol 
HDL cholesterol 
Triglycerides 
Cholesterol / HDL ratio 
LDL / HDL ratio 
  
Chest X- Ray PA view 
ECHO CARDIOGRAPHY 
 V
MASTER CHART I 
DAY - 1 POST MI DAY – 4 POST M I 
Sl. 
No IP Age Sex 
SE 
Status Angina DM HT 
Smo 
king 
Obe 
sity 
FamiIly 
History 
Stemi 
(or) 
Nstemi 
Enzymes Echo 
Kil 
lip 
class 
Total 
Chol TGL 
Cho/ 
HDL 
LDL/ 
HDL 
Total 
Chol TGL 
Cho/ 
HDL 
LDL/ 
HDL 
1 238614 65 M L 3 - - + - - S ↑ + II 190 160 4 .1 2 .4 172 189 4 .3 2 .4 
2 238619 68 M L ½ + - - + - S ↑ + I 223 165 4 .1 2 .5 204 200 4 .3 2 .5 
3 238677 45 M M ½ - - - - - N ↑ + I 213 198 4 .0 2 .3 197 227 4 .1 2 .2 
4 238742 56 F L ½ - + - + + S ↑ + I 160 80 4 .4 3 .0 143 118 4 .7 3 .0 
5 238509 48 M L 1 + + + - + S ↑ + III 140 60 5 .4 3 .9 125 100 6 .2 4 .2 
6 238622 52 M L 1 - - + - - N ↑ + I 228 180 3 .8 2 .2 210 208 3 .8 2 .2 
7 238755 65 M M ½ - + + + - S ↑ + II 163 80 4 .6 3 .0 146 112 4 .8 3 .1 
8 238756 70 M L ½ + - - + + S ↑ + I 240 190 3 .9 2 .2 220 220 4 .0 2 .2 
9 238905 70 M M 1 - - + - - N ↑ + I 138 58 5 .3 3 .8 121 87 5 .5 3 .9 
10 238915 58 M L ¾ - - - - - S ↑ + II 187 121 4 .3 2 .7 171 150 4 .3 2 .6 
11 239080 50 M L 1 - - + - - S ↑ + I 163 82 4 .4 3 .0 146 113 4 .6 3 .0 
12 239100 27 M L 1 + - - - + S ↑ + I 138 60 5 .0 3 .5 120 81 5 .2 3 .6 
13 239109 67 M L ¾ - + - - - S ↑ + I 192 120 4 .1 2 .5 173 150 4 .2 2 .5 
14 239183 53 F L ½ - + - - - N ↑ + I 215 162 4 .0 2 .4 198 183 4 .2 2 .4 
15 239198 69 F M 1 + - - - - S ↑ + I 241 200 3 .8 2 .2 227 218 4 .0 2 .2 
16 239223 70 F L 2 - + - - - S ↑ + II 191 121 4 .1 2 .6 173 152 4 .1 2 .5 
17 239284 65 M L 2 - - + - - S ↑ + I 140 62 4 .8 3 .2 115 88 4 .8 3 .1 
18 239295 46 M L 1 + + + + + S ↑ + II 239 205 3 .9 2 .1 227 217 4 .0 2 .2 
19 239340 68 F L 2 - + - - - S ↑ + I 163 82 4 .4 2 .9 142 115 4 .5 2 .9 
20 239391 60 M L 1 ½ - - + - - S ↑ + II 213 160 4 .0 2 .4 198 183 4 .1 2 .4 
21 239400 70 M L 2 - + - + - N ↑ + I 138 58 5.0 3.5 113 98 4.9 3.2 
22 239438 43 M M 1 - - - - - N ↑ + I 164 80 4.4 3.0 142 110 4.4 2.9 
23 239551 54 M L 2 ½ + - - + - S ↑ + I 238 198 3.8 2.1 228 277 3.9 2.1 
24 239626 55 M M 1 - + - - - S ↑ + I 213 160 4.0 2.4 198 183 4.2 2.5 
25 239640 67 F L 2 - + - - - S ↑ + II 189 120 4.3 2.7 171 150 4.3 2.6 
 
 VI
MASTER CHART II 
                
DAY - 1 POST MI DAY – 4 POST M I 
Sl. 
No IP Age Sex 
SE 
Status 
Ang 
ina DM HT 
Smo 
king 
Obe 
sity 
Fam 
Ily 
His 
tory 
Ste 
mi 
(or) 
Nste 
mi 
Enzy 
mes Echo 
Kil 
lip 
class 
Total 
Chol TGL 
Cho/ 
HDL 
LDL/ 
HDL 
Total 
Chol TGL 
Cho/ 
HDL 
LDL/ 
HDL 
26 239776 65 M M 1 - - - - - S ↑ + I 138 60 5 .3 3 .8 121 91 5 .4 3 .7 
27 239935 75 M L 1 ½ + - - - - S ↑ + III 240 200 3 .8 2 .1 222 230 3 .8 2 .1 
28 240000 65 M L 2 - - - - + S ↑ + I 162 80 4 .5 3 .1 144 108 4 .7 3 .1 
29 240005 65 F L 3 ½ - - - + - S ↑ + I 192 121 4 .2 2 .6 171 150 4 .2 2 .5 
30 240025 70 M L 1 + + + - - S ↑ + I 215 160 3 .9 2 .3 197 190 4 .0 2 .3 
31 240073 49 M L 1 - - + - - S ↑ + II 242 202 3 .8 2 .1 225 235 3 .8 2 .1 
32 240090 76 F M 2 + - - - - S ↑ + I 214 161 4 .0 2 .3 197 192 4 .0 2 .3 
33 240255 40 M L 1 - + + - - N ↑ + I 138 56 5 .1 3 .7 120 87 5 .5 3 .9 
34 240316 67 M L ½ + - - - - S ↑ + II 165 79 4 .5 3 .0 147 108 4 .7 3 .0 
35 240447 75 M L ½ - + - - - N ↑ + I 189 121 4 .1 2 .5 171 150 4 .2 2 .5 
36 240484 56 M M 1 + - + - - N ↑ + I 136 56 5 .3 3 .9 118 87 5 .8 4 .0 
37 240720 45 M L 2 - - - - - S ↑ + II 216 162 4 .0 2 .3 197 191 4 .1 2 .3 
38 240842 86 M L 3 - - - - - S ↑ + IV 163 80 4 .5 3 .1 145 110 4 .6 3 .0 
39 240869 30 F M ½ + - + - + S ↑ + I 187 118 4 .2 2 .7 169 151 4 .2 2 .6 
40 241416 42 M L ½ - + - - - S ↑ + I 238 200 3 .9 2 .2 227 217 4 .0 2 .2 
41 241433 41 M L 1 - - + - - S ↑ + II 163 81 4.5 3.0 142 115 4.5 2.9 
42 241442 55 M L 1 - - - + + S ↑ + II 135 60 4.9 3.3 113 90 4.9 3.2 
43 241525 35 M L 1 ½ - + + - + S ↑ + I 241 205 3.8 2.2 226 217 4.0 2.2 
44 241775 62 M L 1 + - - - - N ↑ + I 214 158 3.9 2.3 198 183 4.2 2.4 
45 241794 60 M M 1 - + - - - S ↑ + II 187 121 4.3 2.7 171 150 4.3 2.6 
46 241899 32 M L 2 - - + - - S ↑ + I 213 160 4.0 2.4 198 183 4.2 2.4 
47 242439 80 F L 1 - - - - - N ↑ + I 240 200 3.8 2.2 227 218 3.9 2.2 
48 242440 65 M L 1 + - - - - S ↑ + II 162 81 4.5 3.0 141 114 4.5 2.9 
49 242579 56 F L 2 - + - - - S ↑ + I 135 58 5.1 3.7 112 101 5.1 3.3 
50 242736 54 M L 2 - - - - - S ↑ + I 241 201 3.8 2.2 228 219 4.0 2.2 
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MASTER CHART III 
 
DAY - 1 POST MI DAY – 4 POST M I 
Sl. 
No IP Age Sex 
SE 
Status 
Ang 
ina DM HT 
Smo 
king 
Obe 
sity 
Fam 
Iy 
His 
tory 
Stemi 
(or) 
NsteMi 
Enzy 
mes Echo 
Kil 
lip 
class 
Total 
Chol TGL 
Cho 
/HDL 
LDL/ 
HDL 
Total 
Chol TGL 
Chol 
/HDL 
LDL/ 
HDL 
51 242434 70 M M 3 + + + - - N ↑ + I 138 51 4 .9 3 .4 112 90 4 .7 3 .0 
52 243449 86 M L ½ - + + - - S ↑ + II 162 80 4 .5 3 .0 142 116 4 .5 2 .8 
53 243468 29 M L ½ - - + - - S ↑ + I 188 119 4 .2 2 .6 171 150 4 .3 2 .6 
54 244526 49 M M ½ + + - + - S ↑ + II 242 200 3 .9 2 .2 228 218 4 .0 2 .2 
55 243548 41 M M 1 - - - - - S ↑ + I 215 159 4 .0 2 .4 198 184 4 .2 2 .4 
56 243931 50 M L 3 - - - - - S ↑ + II 161 93 4 .2 2 .7 151 126 4 .4 2 .7 
57 244503 54 M L 2 + - + - + N ↑ + I 152 65 4 .7 3 .3 132 103 4 .7 3 .0 
58 244516 49 M M 1 - - + - - S ↑ + I 206 171 3 .7 2 .1 189 172 4 .2 2 .5 
59 245345 58 F L 1 + - - - - S ↑ + II 189 121 4 .2 2 .6 170 148 4 .3 2 .6 
60 245392 46 M L 2 - - - - - S ↑ + I 224 171 4 .0 2 .4 206 194 4 .2 2 .4 
61 245529 50 F L 3 + - - - - S ↑ + II 183 114 4 .7 3 .0 166 145 4 .8 3 .0 
62 245583 60 M M 2 - - + - - S ↑ + I 173 104 5 .7 4 .0 155 134 6 .0 4 .1 
63 245612 65 M L 1 - - - - + S ↑ + I 203 134 3 .4 1 .9 185 164 3 .4 1 .9 
64 245719 62 M L 2 - - + - + S ↑ + II 183 114 4 .6 2 .9 165 144 4 .8 2 .9 
65 245772 45 M M 2 - - + - - S ↑ + I 187 118 4 .3 2 .7 169 118 4 .4 2 .7 
66 246263 50 M L 3 - - - + + N ↑ + I 218 149 2 .9 1 .5 201 179 2 .9 1 .4 
67 246280 48 M L 1 - - + - - S ↑ + I 176 108 7 .0 5 .0 158 137 6 .0 4 .7 
68 246466 40 F L 2 + + - - - S ↑ + I 200 131 3 .5 2 .0 182 161 3 .5 2 .0 
69 246934 60 M M 1 - - + - - N ↑ + I 195 125 3 .8 2 .3 177 156 3 .9 2 .3 
70 347056 76 M M 2 - + - + + S ↑ + III 191 122 4 .0 2 .4 173 152 4 .1 2 .4 
71 246760 60 M L 2 - - + - - N ↑ + I 171 93 4 .4 2 .9 152 127 4 .4 2 .7 
72 247343 65 M L 1 - - - - + S ↑ + II 175 99 4 .3 2 .8 157 132 4 .4 2 .8 
73 247373 64 M M 2 - + - - - N ↑ + I 201 139 4 .1 2 .5 185 166 4 .3 2 .5 
74 248212 57 M L 2 + - - - - S ↑ + I 186 117 4 .4 2 .8 168 147 4 .4 2 .8 
75 248545 40 F L 3 ½ - - - - - S ↑ + II 206 146 4 .1 2 .5 189 171 4 .2 2 .5 
 
 VIII
MASTER CHART IV 
 
DAY - 1 POST MI DAY – 4 POST M I 
Sl. 
No IP Age Sex 
SE 
Status 
Ang 
ina DM HT 
Smok 
ing Obesity 
Family 
History 
Stemi 
(or) 
Nstemi 
Enzy 
mes Echo 
Killip 
class 
Total 
Chol TG 
Chol 
/HDL 
LDL/ 
HDL 
Total 
Chol TGL 
Chol 
/HDL 
LDL/ 
HDL 
76 248555 47 M L 1 - + - - - S ↑ + I 178 103 4 .4 2 .8 159 135 4 .4 2 .7 
77 248998 60 M M 1 + + + + - S ↑ + I 170 82 4 .3 2 .9 152 127 4 .3 2 .7 
78 249035 70 M L 1 ½ - - + - - S ↑ + II 208 145 4 .1 2 .5 189 172 4 .2 2 .5 
79 249413 69 M M 1 - + - - - S ↑ + I 202 140 4 .1 2 .4 184 166 4 .1 2 .4 
80 249595 52 M M 2 + - - - - S ↑ + I 187 118 4 .3 2 .7 169 148 4 .4 2 .7 
81 249685 70 M L 1 - - - - - S ↑ + II 152 65 4 .6 3 .0 132 105 4 .6 2 .9 
82 249712 61 M L 2 - + - - - S ↑ + II 224 173 4 .0 2 .4 208 193 4 .1 2 .4 
83 249800 65 F L 1 + + - - - S ↑ + I 162 78 4 .6 3 .0 142 115 4 .7 3 .0 
84 249886 42 F M 1 ½ + - - - - S ↑ + I 215 160 4 .0 2 .4 198 183 4 .2 2 .4 
85 249974 65 M L 1 - - + - - S ↑ + I 189 120 4 .1 2 .5 172 151 4 .1 2 .5 
86 250542 47 M L 1 ½ - - + - - S ↑ + II 205 146 4 .1 2 .5 189 171 4 .2 2 .5 
87 250750 50 M M 2 - - - - - S ↑ + III 227 180 4 .0 2 .3 212 202 4 .1 2 .3 
88 251437 55 M L 1 + - - - - N ↑ + I 162 79 4 .5 3 .0 142 115 4 .5 2 .9 
89 251500 74 M L 2 - - + - - N ↑ + I 170 92 4 .4 2 .9 151 127 4 .4 2 .8 
90 251952 46 F M 1 - + - - - S ↑ + I 206 146 4 .0 2 .5 190 172 4 .2 2 .5 
91 252057 53 F M 2 - - - - - S ↑ + II 214 159 4 .0 2 .4 206 146 4 .0 2 .4 
92 252090 45 M L 1 + - - - - S ↑ + II 162 78 4 .6 3 .0 142 114 4 .7 3 .0 
93 252204 76 M L 2 - - + - - S ↑ + III 214 160 4 .0 2 .4 199 183 4 .2 2 .4 
94 252979 52 M L 1 - - + - - S ↑ + I 201 139 4 .1 2 .5 183 167 4 .1 2 .5 
95 253105 57 M M 2 - - - - - S ↑ + I 186 117 4 .3 2 .8 168 147 4 .4 2 .7 
96 253110 45 M L 1 - - + - - S ↑ + I 198 135 4 .2 2 .6 181 163 4 .3 2 .6 
97 253952 75 M L 2 - - - + - S ↑ + I 175 98 4 .3 2 .7 155 132 4 .4 2 .7 
98 255062 44 M M 1 - + - - - S ↑ + I 187 118 4 .3 2 .7 169 148 4 .4 2 .7 
99 255170 45 M M 2 - + - + - N ↑ + I 164 79 4 .4 2 .9 139 113 4 .7 3 .0 
100 255176 65 M M 1 ¾ + + + + + S ↑ + III 242 202 3 .8 2 .1 227 219 3 .9 2 .2 
 
